For example, RAD51C-G135C is associated with an increased risk of endometrial cancer [RAD51-G135C, C/C: odds ratio (OR) 3.72 (95% confidence interval (CI) 2.77–5.00), C: OR 2.54 (95% CI 2.16–2.99)] and breast cancer [RAD51-G135C, allele model: OR 4.32 (95% CI 2.63–7.10), dominant model: OR 2.28 (95% CI 1.44–3.60), recessive model: OR 10.27 (95% CI 14.71–22.38), homozygous model: OR 7.26 (95% CI 3.59–14.68)] (65,66). Here, RAD51 is linked to endometrial cancer.